Sugammadex and Neostigmine at Shallow Neuromuscular Blockade

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.5) with different doses of either neostigmine or sugammadex.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität München
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Patients ASA physical status I - III

• Patients between 18 and 64 years

• Patients scheduled for general anesthesia with intubation using rocuronium

• Patients having given informed consent to the study

Exclusion Criteria:

• Anatomic and functional malformations with expected difficult intubation

• Known or suspected neuromuscular disease

• Significant hepatic or renal dysfunction

• Known or suspected history or family history of disposition to malignant hyperthermia

• Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other drugs used for general anesthesia

• Use of drugs that interfere with muscle relaxants

• Patients, included in another trial within the last 30 days

• Patients, with legal guidant

• Patients with contraindication towards the use of Sugammadex, neostigmine or glycopyrrolate

• Patients, which have already participated in a sugammadex trial

• Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen, status post tubal ligation)

• Breastfeeding women